| HOME >> BIOLOGY >> TECHNOLOGY |
For further information please contact:
DSM Pharmaceutical Products
Karen King
President
DSM Biologics
Tel: +1-973-257-8427
DSM Biologics
Marcel Lubben
Vice President
Marketing, Sales & NBD
Tel: +31-(0)46-477 3343
Forward-looking statements
This press release contains forward-looking statements that involve inherent risks and uncertainties. These statements are based on current expectations, estimates and projections of the management of DSM and Crucell and information currently available to both companies. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM and Crucell do not guarantee that their expectations will be realized. Furthermore, DSM and Crucell have no obligation to update the statements contained in this press release.
Crucell has identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to the Form 20-F, as filed by Crucell with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". Crucell prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).
| SOURCE DSM Biologics Copyright©2008 PR Newswire. All rights reserved |